Robert J. Alpern - Sep 30, 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Director
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern
Stock symbol
ABBV
Transactions as of
Sep 30, 2025
Transactions value $
$7,641
Form type
4
Date filed
10/2/2025, 05:00 PM
Previous filing
Jul 1, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Alpern Robert J Director 1 N. WAUKEGAN ROAD, NORTH CHICAGO /s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern 2025-10-02 0001448074

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Stock Equivalent Units Award $7.64K +33 +0.33% $231.54 10.2K Sep 30, 2025 Common Stock 33 $231.54 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2 Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.